SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple stock experienced volatility during a product event where the company unveiled the iPhone Duo, its first foldable smartphone, alongside the iPhone 18 Pro series and updated wearables. While some traders expressed skepticism regarding the high price point and late entry into the foldable market, retail sentiment remained mixed as they debated the potential for a "sell the news" reaction versus long-term growth.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a record-breaking second-quarter operating income and an insider purchase of 55,000 shares by director Lawrence Cheng. The community is actively debating the company's future direction, particularly regarding its strategic stake in eBay and the lack of communication on an earnings call, with retail traders split between bullish sentiment on valuation and frustration over price stagnation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is trending following the announcement of a massive share buyback and cancellation program, which investors view as a signal of management's confidence in long-term growth despite recent market volatility. The community remains focused on the company's dominant position in the High Bandwidth Memory (HBM) market and its role in AI infrastructure, though some traders express skepticism regarding the impact of recent Korean regulatory measures on the stock's performance.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending as traders speculate on a major bounce ahead of upcoming earnings, with many viewing the current price as a buying opportunity supported by strong contract backlogs. Debate remains divided between those expecting a sharp reversal fueled by institutional accumulation and others predicting further downside if the company fails to deliver positive guidance.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as investors react to a significant double-digit selloff, with discussion centered on whether the decline represents an unhealthy pullback or a buying opportunity for the AI infrastructure provider. Traders are debating the lack of a clear fundamental catalyst while monitoring key technical support levels to gauge when the stock might recover from the recent volatility.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares fell significantly after the company issued third-quarter revenue guidance that arrived below Street expectations, overshadowing a solid earnings beat. While some traders view the double-digit drop as a major overreaction and a buying opportunity, others express concern over management changes and a potential for further near-term volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following mixed reactions to positive Phase 3 IZAR-1 trial results in psoriatic arthritis, which met primary endpoints but were perceived by some traders as failing to show a clear best-in-class advantage over competitors. Investors remain divided, with many expressing frustration over company management and recent financing moves while others maintain confidence in the firm's long-term potential, citing strong clinical safety profiles and upcoming catalysts.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics is trending after reporting positive Phase 3 clinical trial results for its phentolamine ophthalmic solution in treating presbyopia, which met its primary endpoint. While some traders view the data as a positive catalyst for an eventual FDA submission, others are expressing concern regarding potential dilution or questioning the long-term management strategy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

The discussion is fragmented between traders expressing frustration over the lack of near-term price movement and long-term investors focusing on the company's fundamental growth, specifically the commercial expansion of Recorlev and upcoming Phase 3 trials for XP-8121. While some traders are exiting their positions, others view the recent price consolidation as a buying opportunity given the company's path to profitability and high institutional ownership.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing downward price pressure and investor frustration despite beating earnings expectations and raising guidance, with market sentiment favoring Eli Lilly's stronger growth momentum and pipeline perception. The stock's performance reflects skepticism regarding the competitive impact of alternative obesity treatments and the pace of oral Wegovy's revenue contribution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million.
Estrella Immunopharma (NASDAQ:ESLA)read more...

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1...

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1...

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the...

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6%

Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 265,805 shares, a decrease of 57.6% from the March 31st total of 626,324 shares. Based on an average...

Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% - Here's Why

Estrella Immunopharma (NASDAQ:ESLA) Shares Up 26.5% - Here's What Happened...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA)

D. Boral Capital reissued a "buy" rating and issued a $8.00 price target on shares of Estrella Immunopharma in a research report on Monday...

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Estrella Immunopharma Inc

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Equity

Bearish Sentiment

Yes, day one

Yes, but I'll wait for reviews

No, too expensive

No, not interested in a foldable

Apple unveiled its first foldable iPhone, reportedly called the iPhone Duo, at its September 9 event, with pricing starting at $2,000 for the 256GB model. Will you buy the $2,000 iPhone Duo? Vote and explain your reasoning in the comments.

Apple ($AAPL) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Stocktwits

) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Feed

News

Sentiment

Fundamentals

Info

ESLA Estrella Biopharma Inc

Fundamentals

Latest ESLA News